At 9.0% CAGR, North America Microbiology CRO Services Market is Projected to be Worth US$ 4,952.88 Million by 2031, Says Business Market Insights

According to Business Market Insights' research, the North America microbiology CRO services market was valued at US$ 2,488.24 million in 2023 and is expected to reach US$ 4,952.88 million by 2031, registering a CAGR of 9.0% from 2023 to 2031. Rising practice of outsourcing clinical studies with massive number of trials and rise in partnerships and collaborations with service providers are among the critical factors attributed to the North America microbiology CRO services market expansion.

Clinical trials are conducted to determine if a new form of medical product, drug, diet, or medical device is safe and effective. The trials are mainly a part of the overall drug development process. According to the National Library of Medicine (NLM), ~52,000 new studies were registered with NLM (ClinicalTrials.gov) in 2020, and the number increased to ~58,000 in 2023. In January 2023, the NLM reported 38,837 active clinical trials in the US and 105,172 active trials worldwide. The increasing complexity of clinical trials makes the proper execution and monitoring of operations carried out in research-based organizations crucial. To avoid errors due to improper execution, many research-based organizations outsource clinical trials to clinical research organizations (CROs). Furthermore, CROs assist in successfully implementing clinical trials by offering deep subject matter expertise at high-quality facilities. They have gradually become an important part of the clinical trial industry through their efficient and cost-effective operations that benefit trial sponsors. According to a blog published by Thermo Fisher Scientific, in 2022, CROs executed ~3 out of 4 clinical trials to reassure the clinical programs of drug developers; provide a wealth of expertise; drive time and cost efficiencies; and deliver customized, high-quality data.

Awareness about the importance of microbiology testing in ensuring the quality and safety of products, particularly in the fields of vaccines, biologics, drugs, and medical devices, is increasing. Microbial testing is essential in clinical trials where the integrity of study results relies heavily on accurate microbiology testing. As pharmaceutical companies and biotech firms focus on their core competencies, they are increasingly relying on CROs to manage their clinical trial testing needs. Thus, the increasing number of clinical trials and the practice of outsourcing trials to CROs to boost cost-effectiveness and reduce errors drive the microbiology CRO market.

On the contrary, shortage of skilled professionals hampers the growth of North America microbiology CRO services market.

Based on application, the North America microbiology CRO services market is segmented into clinical, medical device, and others. The clinical segment held 49.9% share of the North America microbiology CRO services market in 2023, amassing US$ 1,242.55 million. It is projected to garner US$ 2,559.13 million by 2031 to expand at 9.5% CAGR during 2023-2031.

Based on service type, the North America microbiology CRO services market is segmented into assay development, custom viral stock production, microbial testing, and others. The microbial testing segment held 59.9% share of the North America microbiology CRO services market in 2023, amassing US$ 1,490.50 million. It is projected to garner US$ 3,015.33 million by 2031 to expand at 9.2% CAGR during 2023-2031.

Based on microorganisms, the North America microbiology CRO services market is segmented into bacteria, fungi, viruses, and parasites. The bacteria segment held 45.2% share of the North America microbiology CRO services market in 2023, amassing US$ 1,125.17 million. It is projected to garner US$ 2,285.96 million by 2031 to expand at 9.3% CAGR during 2023-2031.

Based on end user, the North America microbiology CRO services market is segmented into biotech and pharmaceutical companies, medical device companies, and others. The biotech and pharmaceutical companies segment held 55.2% share of the North America microbiology CRO services market in 2023, amassing US$ 1,374.06 million. It is projected to garner US$ 2,786.51 million by 2031 to expand at 9.2% CAGR during 2023-2031.

Based on country, the North America microbiology CRO services market is segmented into the US, Canada, and Mexico. The US held 90.6% share of North America microbiology CRO services market in 2023, amassing US$ 2,253.10 million. It is projected to garner US$ 4,523.73 million by 2031 to expand at 9.1% CAGR during 2023-2031.

Key players operating in the microbiology CRO services market are Microbiologics; Melbec Microbiology; Emery Pharma; TheraIndx Lifesciences Pvt. Ltd.; AVERIN BIOTECH; Statens Serum Institut; ImQuest BioSciences; PACIFIC BIOLABS; Innovotech Inc.; and BluTest Laboratories Ltd, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com